Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: secondary analysis of the randomised LODESTAR trial (2023)

If ChatGPT’s calculation is correct then yes we cannot conclude with certainty about atorvastatin but the signal in its favor is quite strong.

Regarding neurocognitive decline, I think that obicetrapib is the most promising: Obicetrapib (CETP inhibitor for dyslipidemia)

In the absence of obicetrapib, ezetimibe is my best guess and I think that’s what I’ll start using. Reasoning here: Parkinson's disease - #89 by adssx

Some PD researchers and practicians now support statin cessation in PD patients. See also this discussion: Rapamycin and risk of cardiovascular disease - #3064 by adssx

4 Likes